A study of maternally derived measles antibody in infants born to naturally infected and vaccinated women

Brugha, Ruairı́; Ramsay, Mary; Forsey, T.; Brown, David

doi:10.1017/s0950268800059203

Cited by 54 publications

(43 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have shown that newborns from vaccinated mothers have both lower levels of transplacentally transferred measles antibodies than infants born from women who had measles and an earlier decline in maternal antibodies (1,4,12,15,30,37,38,40). In this study, the measles antibody levels determined for infants at 0 to 3 months of age were higher in infants born from mothers who had had natural measles infections than in infants of vaccinated mothers.…”

Section: Discussionmentioning

confidence: 50%

See 1 more Smart Citation

Kinetics of Decline of Maternal Measles Virus-Neutralizing Antibodies in Sera of Infants in France in 2006

Gagneur

Pinquier

Aubert

et al. 2008

Clin Vaccine Immunol

View full text Add to dashboard Cite

The optimal age for measles vaccination is an important health issue, since maternal antibodies may neutralize the vaccine antigen before a specific immune response develops, while delaying vaccination may increase the risk of complicated diseases in infants. However, measles vaccination impacts the duration of protection afforded by transplacental transfer of maternal antibodies: vaccination-induced maternal antibodies disappear faster than disease-induced antibodies. In order to maintain protection against measles in infants, it is important to monitor the dynamics of this phenomenon in vaccinated populations. To assess the current situation in France, a multicenter, prospective seroepidemiological study was conducted in seven French hospitals between October 2005 and January 2007. Maternal measles antibody concentrations from 348 infants 0 to 15 months old were measured using the plaque reduction neutralization assay. Geometric mean concentrations and the percentage of infants with maternal measles antibody concentrations above the protection threshold (>120 mIU/ml) were assessed according to age. Results show that after more than 20 years of routine measles vaccination in France, maternal measles-neutralizing antibodies decrease dramatically in French infants by 6 months of age, from 1,740 mIU/ml for infants 0 to 1 month old to 223 mIU/ml for infants 5 to 6 months old, and that 90% of infants are not protected against measles after 6 months of age. Infant protection against measles could be optimized both by increasing herd immunity through an increased vaccine coverage and by lowering the age of routine vaccination from 12 to 9 months.

show abstract

Section: Discussionmentioning

confidence: 50%

“…Measles vaccine coverage of infants (with a single dose at 24 months of age) increased from 19% in 1979 to 35% in 1983, 57% in 1987, and 80% in 1994 and then remained relatively unchanged until 2004, when it reached 87% (4,10).…”

mentioning

confidence: 99%

Kinetics of Decline of Maternal Measles Virus-Neutralizing Antibodies in Sera of Infants in France in 2006

Gagneur

Pinquier

Aubert

et al. 2008

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…(19,34,35) .This low observed occurrence in children of vaccination and mothers with a past history of measles be able to explained through the information that these mothers have naturally acquired protection against measles, which provides passive defense to their infants (36) .The attendance of IgM antibodies to MV in serum is analytic of innate measles disease or vaccination.…”

Section: Resultsmentioning

confidence: 99%

Evaluating the prevalence measles virus IgM antibodies for under 2 years children in Diayala governorate

Mohsin¹

2017

DJPS

View full text Add to dashboard Cite

The goal of present study was to evaluating the prevalence of measles virus (MV) immunoglobulin M antibodies in children under two year. This study was conducted from the (41%) among children of mothers with unvaccinated or no a past history of measles. Finally, the prevalence of IgM was 2(2.6%) in children who were breast feeding, but 33(37.9%) among non-breastfeeding children. In conclusion, the prevalence of anti-MV IgM was higher among aged (0-8) months. For the more, the prevalence of IgM was higher among females.Additionally prevalence it's higher among unvaccinated children. While prevalence its higher among children of mothers with unvaccinated or no history of measles. Finally, the prevalence it's higher among non-breastfeeding children..

show abstract

“…Similarly, Sethi et al found that IgG levels of low-birth-weight newborns (weighing less than 2 standard deviations below the expected weight for gestational age due to maternal illness during pregnancy) were lower than the antibody levels of normal weight infants of healthy mothers [25]. It is obvious that the decrease in serum IgG levels in infants born to mothers with antenatal illness is mainly due to the effects of maternal malnutrition and may possibly be related to the placental pathology commonly observed in these pregnancies [26].…”

Section: Discussionmentioning

confidence: 99%

“…Although our study did not include measuring maternal antibodies to the 3 diseases in the mothers of the studied infants, it is assumed to be highest among mothers with a history of infection. A study conducted in both developing and developed countries that measured maternal-specific antibodies to measles found that mothers who contracted measles had significantly higher levels of antibodies and higher seroprevalence rates among their infants than mothers who were vaccinated [26]. It has been suggested that the children of women who have received measles vaccine might be successfully immunized at an earlier age than the children of women who have had measles [14].…”

Section: Discussionmentioning

confidence: 99%

Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?

Abbassy¹,

Barakat²,

Fattah³

et al. 2009

East Mediterr Health J

View full text Add to dashboard Cite

Le calendrier vaccinal actuel (rougeole à 9 mois et ROR à 18 mois) peut-il être remplacé par une dose de ROR à 1 an en Égypte ? RÉSUMÉ Cette étude transversale a évalué le statut immunitaire de nourrissons en bonne santé non vaccinés afin de déterminer la possibilité de remplacer le calendrier vaccinal actuel, qui prévoit un vaccin antirougeoleux à 9 mois et un vaccin antirougeoleux-antiourlien-antirubéoleux (ROR) à 18 mois, par une dose unique de vaccin ROR à 12 mois. Les échantillons de sérum prélevés sur 566 enfants d'Alexandrie (Égypte) ont montré une baisse significative du taux de séropositivité aux trois maladies virales à mesure que l'âge augmentait, mais une augmentation significative de ce taux chez les nourrissons qui étaient le premier ou le deuxième enfant de la famille, nés à terme ou de mères n'ayant pas d'antécédents d'hypertension pendant la grossesse. Nous recommandons l'administration de la première dose de vaccin ROR entre 9 et 12 mois et une dose de rappel à l'âge de 4 ans. ABSTRACT This cross-sectional study evaluated the immune status of non-vaccinated healthy infants to determine if it is possible to replace both measles vaccine (at 9 months) and measles, mumps and rubella (MMR) vaccine (at 18 months) with a single dose of MMR at 12 months. Serum samples from 566 children in Alexandria, Egypt showed a significant decrease in the seropositive rate to the 3 viral diseases with increasing age, but a significant increase in the seropositive rate among infants who were ranked 1st or 2nd in their family, full-term or born to mothers with no history of hypertension during pregnancy. We recommend administration of the first dose of MMR vaccine between 9 and 12 months of age, and a booster dose of MMR vaccine at 4 years of age. 86La Revue de Santé de la Méditerranée orientale, Vol. 15, N°

show abstract

A study of maternally derived measles antibody in infants born to naturally infected and vaccinated women

Cited by 54 publications

References 24 publications

Kinetics of Decline of Maternal Measles Virus-Neutralizing Antibodies in Sera of Infants in France in 2006

Kinetics of Decline of Maternal Measles Virus-Neutralizing Antibodies in Sera of Infants in France in 2006

Evaluating the prevalence measles virus IgM antibodies for under 2 years children in Diayala governorate

Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?

Contact Info

Product

Resources

About